- Matica Biotechnology has secured over 10 new cell and gene therapy manufacturing projects in H1 2025, surpassing its total 2024 revenue.
- The company’s U.S.-based CDMO services now span preclinical to commercial stages, supported by its purpose-built College Station facility and proprietary MatiMAX™ platform.
Matica Biotechnology, Inc., a U.S.-based CDMO specialising in cell and gene therapies (CGT), announced it has secured more than 10 new manufacturing projects in the first half of 2025, surpassing its total 2024 revenue by Q2. The projects cover preclinical to commercial stages and involve a diverse client base, including emerging biotech startups and publicly traded firms.
A notable milestone includes a commercial manufacturing agreement with a mid-sized U.S. biotech for late-stage production of a viral vector therapy. This demonstrates Matica’s capability to support complex, regulatory-intensive programmes at scale.
The company’s growth is anchored by its purpose-built CGT facility in College Station, Texas. Designed exclusively for viral vector manufacturing, the site features a fully single-use system to enhance productivity, facilitate scale-up, and reduce contamination risk. Matica’s proprietary MatiMAX™ cell line platform for AAV and LVV production, alongside advanced in-house capabilities such as full-to-empty capsid analysis, ensures consistent quality and regulatory readiness.
“This year’s momentum reflects the trust our clients place in our facility, team, and technology. Just last month, we secured two additional major GMP projects, further validating our approach and capabilities. We’re proud to support our partners across all stages of development with customised, compliant, and scalable manufacturing solutions delivered here in the U.S., as well as in Asia Pacific with Cha Group Hospitals and Medical University.”
Paul Kim, CEO of Matica Biotechnology
Matica differentiates itself through a flexible, client-focused approach. Each project is tailored to meet specific scientific, technical, and regulatory requirements, offering supply chain stability and full compliance with FDA guidelines. Looking ahead to 2026, the company plans further capacity expansion and strategic collaborations to meet growing demand for next-generation cell and gene therapies.
